ReviewReviews in neurological diseases2008
The treatment of giant cell arteritis.
Review in Reviews in neurological diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 70 citations in OpenAlex.
- Tocilizumab for relapsing and remitting giant cell arteritis: a case series.Journal of medical case reports · 2022Article
- Giant Cell Arteritis: A Case-Based Narrative Review of the Literature.Current pain and headache reports · 2022Review
- Ocular Complications of Giant Cell Arteritis: An Acute Therapeutic Emergency.Journal of clinical medicine · 2022Review
- Evidence-based Role of Aspirin in Giant Cell Arteritis: A Literature Review.Journal of community hospital internal medicine perspectives · 2022Review
- Giant cell arteritis complicated by tongue necrosis and bilateral cerebellar ischaemic stroke.BMJ case reports · 2021Article
- Targeted RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Temporal Arteries From Giant Cell Arteritis Cases Reveals Viral Signatures.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Neuro-Ophthalmic Emergencies.Neurologic clinics · 2021Review
- Corticosteroid Usage in Giant Cell Arteritis.Neuro-ophthalmology (Aeolus Press) · 2021Article
- Very Poor Visual Acuity in Non-Arteritic Anterior Ischaemic Optic Neuropathy.Neuro-ophthalmology (Aeolus Press) · 2021Article
- A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis.Rheumatology and therapy · 2020Article
- Considerations for the Treatment of Inflammatory Neuro-Ophthalmologic Disorders During the COVID-19 Pandemic.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2020Review
- Cytomegalovirus Retinal Necrosis With Occlusive Vasculopathy Secondary to Steroid Immunosuppression for Giant Cell Arteritis.Journal of vitreoretinal diseases · 2020Article
- Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database.Rheumatology and therapy · 2019Article
- Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data.Rheumatology and therapy · 2019Article
- Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis.ClinicoEconomics and outcomes research : CEOR · 2019Article
- Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK.Rheumatology and therapy · 2018Article
- Combined bilateral ophthalmic artery occlusion & central retinal vein occlusion from presumed giant cell arteritis.American journal of ophthalmology case reports · 2018Article
- Orbitocerebral mucormycosis and intracranial haemorrhage: a role for caution with steroids in suspected giant cell arteritis.BMJ case reports · 2018Article
- The Treatment of Giant Cell Arteritis.Current treatment options in neurology · 2017Review
- Giant cell arteritis: a closer look at its ophthalmological manifestations.BMJ case reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Although giant cell arteritis (GCA) is a well-known vasculitis sensitive to corticosteroid-mediated immunosuppression, numerous issues of long-term therapeutic management remain unresolved. Because GCA encompasses a broad spectrum of clinical subtypes, ranging from devastating visual loss and neurological deficits to isolated systemic symptoms, the treatment of GCA must be adjusted to each case, and recommendations vary widely in the literature. This article systematically reviews the treatment options for patients with neuro-ophthalmic and neurological complications of GCA, as well as the evidence for possible adjuvant therapies for patients with GCA. Although there is no randomized controlled clinical trial specifically evaluating GCA patients with ocular and neurological complications, we recommend that GCA patients with acute visual loss or brain ischemia be admitted to the hospital for high-dose intravenous methyl-prednisolone, close monitoring, and prevention of steroid-induced complications. Aspirin may also be helpful in these cases. The evidence supporting the use of steroid-sparing immunomodulatory agents such as methotrexate for long-term management remains debated.
Indexed as
Identifiers
18838954PMC3014829W1788988135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.